MedPath

AMPED Outcomes Registry of Post-ED Pain Management

Completed
Conditions
Soft Tissue Injuries
Gouty Arthritis
Fractures
Ureteral Colic
Dysmenorrhea
Registration Number
NCT01626235
Lead Sponsor
Radnor Registry Research, Inc
Brief Summary

Study aims to assess patient-recorded outcomes of pain control medications prescribed in the ER after visits for specific painful injuries/illnesses.

Detailed Description

Multicenter, observational, prospective, out-of-hospital registry collecting clinical, satisfaction, quality of life, and healthcare resource utilization from subjects discharged after ED care for a specific acute pain syndrome with a clinician-determined analgesic regimen. Subjects are stratified by diagnosis and by regimen based on the treating clinician's judgment. The registry study is independent of ED care and clinician's decision-making.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
843
Inclusion Criteria
  • Eligible subjects will meet the following criteria:

    1. Eligible diagnoses:

      musculoskeletal etiologies: acute extremity fractures sprains/strains acute gouty arthritis visceral etiologies: renal colic dysmenorrhea

    2. Age GTE 18 years;

    3. Decision to discharge from ED to community already made;

    4. Decision to give SPRIX, opioid, OR SPRIX + opioid rescue already made;

    5. Treating clinician deems patient appropriate for continued analgesic management as an outpatient for the next 3-5 days;

    6. Patient has ready touch-tone (mobile or land line) telephone access, provides number (and back-up number, if possible) and agrees (verbal or written consent as mandated by site) to answer and comply with brief IVR questionnaires daily for next 4 days.

Exclusion Criteria
  • Eligible subjects will meet none of the following criteria:

    1. Patient admitted or placed on observation status from ED;
    2. Patient unwilling or unable to comply with telephonic follow-up;
    3. Fracture that requires surgical repair (even if at a later date);
    4. Patient has diagnosis of any chronic pain syndrome;
    5. Patient already routinely takes NSAID or opioid agent;
    6. Treating clinician has reasonable suspicion of drug-seeking behavior or noncompliance;
    7. Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical Outcomes of pain control measures5 days

1. Change in pain score over follow-up interval;

2. Healthcare resource utilization during follow-up interval;

3. Patient satisfaction with therapy;

4. Return to work in employed cohort.

Secondary Outcome Measures
NameTimeMethod
Satisfaction and Economic Outcomes5 days

1. Effectiveness of work upon return;

2. Relative adverse effect profiles of three treatment regimens;

3. Compliance with therapy;

4. QOL at conclusion of therapy.

Trial Locations

Locations (10)

University of Texas HSC at Houston

🇺🇸

Houston, Texas, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Oklahoma HSC

🇺🇸

Tulsa, Oklahoma, United States

Pennsylvania Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

LSU Medical Center

🇺🇸

New Orleans, Louisiana, United States

Ben Taub General Hospital

🇺🇸

Houston, Texas, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath